- Home
- SOTK vs MAIA Comparison
SOTK vs MAIA Comparison
Compare SOTK & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOTK
- MAIA
- Stock Information
- Founded
- SOTK 1975
- MAIA 2018
- Country
- SOTK United States
- MAIA United States
- Employees
- SOTK N/A
- MAIA N/A
- Industry
- SOTK Industrial Machinery/Components
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SOTK Technology
- MAIA Health Care
- Exchange
- SOTK Nasdaq
- MAIA Nasdaq
- Market Cap
- SOTK 58.5M
- MAIA 46.7M
- IPO Year
- SOTK 1987
- MAIA 2022
- Fundamental
- Price
- SOTK $3.66
- MAIA $1.88
- Analyst Decision
- SOTK Hold
- MAIA
- Analyst Count
- SOTK 1
- MAIA 0
- Target Price
- SOTK N/A
- MAIA N/A
- AVG Volume (30 Days)
- SOTK 5.4K
- MAIA 536.7K
- Earning Date
- SOTK 07-10-2025
- MAIA 08-08-2025
- Dividend Yield
- SOTK N/A
- MAIA N/A
- EPS Growth
- SOTK N/A
- MAIA N/A
- EPS
- SOTK 0.09
- MAIA N/A
- Revenue
- SOTK $20,606,116.00
- MAIA N/A
- Revenue This Year
- SOTK N/A
- MAIA N/A
- Revenue Next Year
- SOTK $9.53
- MAIA N/A
- P/E Ratio
- SOTK $40.42
- MAIA N/A
- Revenue Growth
- SOTK N/A
- MAIA N/A
- 52 Week Low
- SOTK $3.50
- MAIA $1.40
- 52 Week High
- SOTK $6.05
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- SOTK 50.01
- MAIA 56.41
- Support Level
- SOTK $3.63
- MAIA $1.80
- Resistance Level
- SOTK $3.78
- MAIA $2.15
- Average True Range (ATR)
- SOTK 0.13
- MAIA 0.13
- MACD
- SOTK 0.00
- MAIA 0.02
- Stochastic Oscillator
- SOTK 52.38
- MAIA 60.00
About SOTK Sono-Tek Corporation
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.